Cargando…
Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers
BACKGROUND: Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946517/ https://www.ncbi.nlm.nih.gov/pubmed/27500266 http://dx.doi.org/10.1097/TXD.0000000000000588 |
_version_ | 1782443038465851392 |
---|---|
author | Pratschke, Sebastian Arnold, Hannah Zollner, Alfred Heise, Michael Pascher, Andreas Schemmer, Peter Scherer, Marcus N. Bauer, Andreas Jauch, Karl-Walter Werner, Jens Guba, Markus Angele, Martin K. |
author_facet | Pratschke, Sebastian Arnold, Hannah Zollner, Alfred Heise, Michael Pascher, Andreas Schemmer, Peter Scherer, Marcus N. Bauer, Andreas Jauch, Karl-Walter Werner, Jens Guba, Markus Angele, Martin K. |
author_sort | Pratschke, Sebastian |
collection | PubMed |
description | BACKGROUND: Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI. The tacrolimus organ perfusion study was initiated to examine the effects of ex vivo tacrolimus perfusion on IRI in transplantation of EDC livers. METHODS: A prospective randomized multicenter trial comparing ex vivo perfusion of marginal liver grafts (≥2 EDC according to Eurotransplant manual) with tacrolimus (20 ng/mL) or histidine-tryptophane-ketoglutarate solution (control) was carried out at 5 German liver transplant centers (Munich Ludwig-Maximilians University, Berlin, Heidelberg, Mainz, Regensburg) between October 2011 and July 2013. Primary endpoint was the maximum alanine transaminase (ALT) level within 48 hours after transplantation. Secondary endpoints were aspartate transaminase (AST), prothrombine ratio, and graft-patient survival within an observation period of 1 week. After an interim analysis, the study was terminated by the scientific committee after the treatment of 24 patients (tacrolimus n = 11, Control n = 13). RESULTS: Tacrolimus rinse did not reduce postoperative ALT peaks compared with control (P = 0.207; tacrolimus: median, 812; range, 362-3403 vs control: median, 652; range, 147-2034). Moreover, ALT (P = 0.100), prothrombine ratio (P = 0.553), and bilirubin (P = 0.815) did not differ between the groups. AST was higher in patients treated with tacrolimus (P = 0.011). Survival was comparable in both groups (P > 0.05). CONCLUSIONS: Contrary to experimental findings, tacrolimus rinse failed to improve the primary endpoint of the study (ALT). Because 1 secondary endpoint (AST) was even higher in the intervention group, the study was terminated prematurely. Thus, tacrolimus rinse cannot be recommended in transplantation of EDC livers. |
format | Online Article Text |
id | pubmed-4946517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-49465172016-08-05 Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers Pratschke, Sebastian Arnold, Hannah Zollner, Alfred Heise, Michael Pascher, Andreas Schemmer, Peter Scherer, Marcus N. Bauer, Andreas Jauch, Karl-Walter Werner, Jens Guba, Markus Angele, Martin K. Transplant Direct Liver Transplantation BACKGROUND: Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI. The tacrolimus organ perfusion study was initiated to examine the effects of ex vivo tacrolimus perfusion on IRI in transplantation of EDC livers. METHODS: A prospective randomized multicenter trial comparing ex vivo perfusion of marginal liver grafts (≥2 EDC according to Eurotransplant manual) with tacrolimus (20 ng/mL) or histidine-tryptophane-ketoglutarate solution (control) was carried out at 5 German liver transplant centers (Munich Ludwig-Maximilians University, Berlin, Heidelberg, Mainz, Regensburg) between October 2011 and July 2013. Primary endpoint was the maximum alanine transaminase (ALT) level within 48 hours after transplantation. Secondary endpoints were aspartate transaminase (AST), prothrombine ratio, and graft-patient survival within an observation period of 1 week. After an interim analysis, the study was terminated by the scientific committee after the treatment of 24 patients (tacrolimus n = 11, Control n = 13). RESULTS: Tacrolimus rinse did not reduce postoperative ALT peaks compared with control (P = 0.207; tacrolimus: median, 812; range, 362-3403 vs control: median, 652; range, 147-2034). Moreover, ALT (P = 0.100), prothrombine ratio (P = 0.553), and bilirubin (P = 0.815) did not differ between the groups. AST was higher in patients treated with tacrolimus (P = 0.011). Survival was comparable in both groups (P > 0.05). CONCLUSIONS: Contrary to experimental findings, tacrolimus rinse failed to improve the primary endpoint of the study (ALT). Because 1 secondary endpoint (AST) was even higher in the intervention group, the study was terminated prematurely. Thus, tacrolimus rinse cannot be recommended in transplantation of EDC livers. Lippincott Williams & Wilkins 2016-05-04 /pmc/articles/PMC4946517/ /pubmed/27500266 http://dx.doi.org/10.1097/TXD.0000000000000588 Text en Copyright © 2016 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Liver Transplantation Pratschke, Sebastian Arnold, Hannah Zollner, Alfred Heise, Michael Pascher, Andreas Schemmer, Peter Scherer, Marcus N. Bauer, Andreas Jauch, Karl-Walter Werner, Jens Guba, Markus Angele, Martin K. Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers |
title | Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers |
title_full | Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers |
title_fullStr | Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers |
title_full_unstemmed | Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers |
title_short | Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers |
title_sort | results of the top study: prospectively randomized multicenter trial of an ex vivo tacrolimus rinse before transplantation in edc livers |
topic | Liver Transplantation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946517/ https://www.ncbi.nlm.nih.gov/pubmed/27500266 http://dx.doi.org/10.1097/TXD.0000000000000588 |
work_keys_str_mv | AT pratschkesebastian resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT arnoldhannah resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT zollneralfred resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT heisemichael resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT pascherandreas resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT schemmerpeter resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT scherermarcusn resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT bauerandreas resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT jauchkarlwalter resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT wernerjens resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT gubamarkus resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers AT angelemartink resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers |